CytomX Therapeutics Net Income
| CTMX Stock | USD 6.10 0.00 0.00% |
As of the 2nd of February, CytomX Therapeutics shows the Risk Adjusted Performance of 0.1292, mean deviation of 3.82, and Downside Deviation of 4.65. CytomX Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
CytomX Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.3442 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 36.6 M | 38.5 M | |
| Net Income From Continuing Ops | 36.6 M | 38.5 M | |
| Net Loss | -104.3 M | -109.5 M | |
| Net Income Per Share | 0.34 | 0.36 | |
| Net Income Per E B T | 1.14 | 1.02 |
CytomX | Net Income | Build AI portfolio with CytomX Stock |
The evolution of Net Income for CytomX Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how CytomX Therapeutics compares to historical norms and industry peers.
Latest CytomX Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of CytomX Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CytomX Therapeutics financial statement analysis. It represents the amount of money remaining after all of CytomX Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CytomX Therapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 31.87 M | 10 Years Trend |
|
Net Income |
| Timeline |
CytomX Net Income Regression Statistics
| Arithmetic Mean | (32,437,225) | |
| Geometric Mean | 30,392,038 | |
| Coefficient Of Variation | (138.19) | |
| Mean Deviation | 36,174,611 | |
| Median | (30,310,000) | |
| Standard Deviation | 44,826,259 | |
| Sample Variance | 2009.4T | |
| Range | 140.7M | |
| R-Value | 0.19 | |
| Mean Square Error | 2069.6T | |
| R-Squared | 0.03 | |
| Significance | 0.48 | |
| Slope | 1,646,397 | |
| Total Sum of Squares | 32150.3T |
CytomX Net Income History
Other Fundumenentals of CytomX Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CytomX Therapeutics Net Income component correlations
CytomX Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Net Income. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. Projected growth potential of CytomX fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CytomX Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.606 | Earnings Share 0.3 | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets |
CytomX Therapeutics's market price often diverges from its book value, the accounting figure shown on CytomX's balance sheet. Smart investors calculate CytomX Therapeutics' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since CytomX Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between CytomX Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CytomX Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CytomX Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytomX Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytomX Therapeutics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in CytomX Therapeutics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding CytomX Therapeutics or generate 0.0% return on investment in CytomX Therapeutics over 90 days. CytomX Therapeutics is related to or competes with Erasca, Iovance Biotherapeutics, MBX Biosciences, ArriVent BioPharma, MeiraGTx Holdings, Astria Therapeutics, and MoonLake Immunotherapeuti. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States More
CytomX Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytomX Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytomX Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.65 | |||
| Information Ratio | 0.1588 | |||
| Maximum Drawdown | 30.43 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 10.08 |
CytomX Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytomX Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytomX Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytomX Therapeutics historical prices to predict the future CytomX Therapeutics' volatility.| Risk Adjusted Performance | 0.1292 | |||
| Jensen Alpha | 0.9168 | |||
| Total Risk Alpha | 0.6689 | |||
| Sortino Ratio | 0.1959 | |||
| Treynor Ratio | 1.12 |
CytomX Therapeutics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1292 | |||
| Market Risk Adjusted Performance | 1.13 | |||
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.12 | |||
| Downside Deviation | 4.65 | |||
| Coefficient Of Variation | 600.29 | |||
| Standard Deviation | 5.74 | |||
| Variance | 32.95 | |||
| Information Ratio | 0.1588 | |||
| Jensen Alpha | 0.9168 | |||
| Total Risk Alpha | 0.6689 | |||
| Sortino Ratio | 0.1959 | |||
| Treynor Ratio | 1.12 | |||
| Maximum Drawdown | 30.43 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 10.08 | |||
| Downside Variance | 21.64 | |||
| Semi Variance | 16.97 | |||
| Expected Short fall | (4.48) | |||
| Skewness | 1.29 | |||
| Kurtosis | 6.32 |
CytomX Therapeutics Backtested Returns
CytomX Therapeutics appears to be relatively risky, given 3 months investment horizon. CytomX Therapeutics secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12 % return per unit of risk over the last 3 months. By analyzing CytomX Therapeutics' technical indicators, you can evaluate if the expected return of 0.7% is justified by implied risk. Please makes use of CytomX Therapeutics' Risk Adjusted Performance of 0.1292, downside deviation of 4.65, and Mean Deviation of 3.82 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, CytomX Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 0.84, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CytomX Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CytomX Therapeutics is expected to be smaller as well. Please check CytomX Therapeutics' potential upside, as well as the relationship between the accumulation distribution and relative strength index , to make a quick decision on whether CytomX Therapeutics' price patterns will revert.
Auto-correlation | 0.16 |
Very weak predictability
CytomX Therapeutics has very weak predictability. Overlapping area represents the amount of predictability between CytomX Therapeutics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytomX Therapeutics price movement. The serial correlation of 0.16 indicates that over 16.0% of current CytomX Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.16 | |
| Spearman Rank Test | 0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.54 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
CytomX Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CytomX Therapeutics reported net income of 31.87 M. This is 90.66% lower than that of the Biotechnology sector and 54.5% lower than that of the Health Care industry. The net income for all United States stocks is 94.42% higher than that of the company.
CytomX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in net income category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 277.8M | 105.2M | 114.4M | 87.0M | 100.0M | 95.0M | |
| Enterprise Value | 93.9M | (70.4M) | 111.2M | 58.3M | 67.1M | 63.7M |
CytomX Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CytomX Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CytomX Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CytomX Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in CytomX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of CytomX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CytomX Therapeutics' value.| Shares | Prosight Management, Lp | 2025-06-30 | 3.5 M | Baker Bros Advisors Lp | 2025-06-30 | 3.5 M | Rtw Investments, Llc | 2025-06-30 | 3.5 M | Adar1 Capital Management Llc | 2025-06-30 | 3.1 M | Balyasny Asset Management Llc | 2025-06-30 | 2.9 M | Ra Capital Management, Llc | 2025-06-30 | 2.7 M | Blackrock Inc | 2025-06-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.4 M | Woodline Partners Lp | 2025-06-30 | 2.3 M | Vr Adviser, Llc | 2025-06-30 | 14 M | Tang Capital Management Llc | 2025-06-30 | 11.1 M |
CytomX Fundamentals
| Return On Equity | 0.67 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | (2.64) % | ||||
| Current Valuation | 834.53 M | ||||
| Shares Outstanding | 169.44 M | ||||
| Shares Owned By Insiders | 0.57 % | ||||
| Shares Owned By Institutions | 88.57 % | ||||
| Number Of Shares Shorted | 16.12 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 9.06 X | ||||
| Price To Sales | 8.48 X | ||||
| Revenue | 138.1 M | ||||
| Gross Profit | 113.63 M | ||||
| EBITDA | 26.76 M | ||||
| Net Income | 31.87 M | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 9.38 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | 0.65 X | ||||
| Cash Flow From Operations | (86.23 M) | ||||
| Short Ratio | 5.45 X | ||||
| Earnings Per Share | 0.30 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 119 | ||||
| Beta | 2.42 | ||||
| Market Capitalization | 964.09 M | ||||
| Total Asset | 120.53 M | ||||
| Retained Earnings | (691.58 M) | ||||
| Working Capital | 21.53 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 120.53 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.